RT Journal Article
T1 Helicobacter pylori serological biomarkers of gastric cancer risk in the MCC-Spain case-control Study.
A1 Fernandez de Larrea-Baz, Nerea
A1 Perez-Gomez, Beatriz
A1 Michel, Angelika
A1 Romero, Beatriz
A1 Lope, Virginia
A1 Pawlita, Michael
A1 Fernandez-Villa, Tania
A1 Moreno, Victor
A1 Martín, Vicente
A1 Willhauck-Fleckenstein, Martina
A1 Lopez-Abente, Gonzalo
A1 Castilla, Jesús
A1 Fernandez-Tardon, Guillermo
A1 Dierssen-Sotos, Trinidad
A1 Santibañez, Miguel
A1 Peiro, Rosana
A1 Jimenez-Moleon, Jose-Juan
A1 Navarro, Carmen
A1 Castaño-Vinyals, Gemma
A1 Kogevinas, Manolis
A1 Pollan, Marina
A1 de Sanjose, Silvia
A1 Del Campo, Rosa
A1 Waterboer, Tim
A1 Aragones, Nuria
K1 Biomarkers
K1 Case-control studies
K1 Gastric neoplasm
K1 Helicobacter pylori infection
K1 Multiplex serology
AB Helicobacter pylori infection is one of the main risk factors for non-cardia gastric cancer. However, only a minority of infected persons develop the disease. This study aims at identifying H. pylori related serological biomarkers of risk for gastric cancer. Incident gastric cancer cases and population controls (age, sex and region frequency-matched) from the MCC-Spain multicase-control Study were included. Seroreactivities against 16H. pylori proteins were determined using multiplex serology. Infection was defined as seropositivity against≥4 proteins. Relation of serological results to non-cardia and cardia gastric cancer was assessed using multivariable mixed logistic regression and principal components analysis. Seroprevalence was 88% among 2071 controls, 95% among 202 non-cardia gastric cancer cases (OR=1.9 (95% CI: 1.0-3.6)) and 85% among 62 cardia cancer cases (OR=0.5 (95% CI: 0.3-1.1)). In infected subjects, seropositivity for UreA, HP231, NapA and Cagδ was associated with lower non-cardia gastric cancer risk, while seropositivity for CagA and VacA was associated with higher risk. Seropositivity for CagA and seronegativity for Cagδ maintained the association after additional adjustment by serostatus of significant proteins. We identified two antibody reactivity patterns: the "virulent-pattern", related to a threefold higher risk of non-cardia gastric cancer and the "non-virulent pattern", related to a 60% decreased risk (4th vs. first quartile). In our population, people seropositive for H. pylori were characterized by two patterns of antibody reactivity against H. pylori proteins: 1) Combined high seroreactivity against several proteins, associated with a lower non-cardia gastric cancer risk, and 2) High seroreactivity against CagA and VacA, associated with an increased risk.
YR 2017
FD 2017-09-07
LK http://hdl.handle.net/10668/11567
UL http://hdl.handle.net/10668/11567
LA en
NO Fernández de Larrea-Baz N, Pérez-Gómez B, Michel A, Romero B, Lope V, Pawlita M, F et al. Helicobacter pylori serological biomarkers of gastric cancer risk in the MCC-Spain case-control Study. Cancer Epidemiol. 2017 Oct;50(Pt A):76-84.
DS RISalud
RD Sep 3, 2025